Review: Several Classes of Drugs Treat Pain of Diabetic Neuropathy

This article originally appeared here.
Share this content:
Review: Several Classes of Drugs Treat Pain of Diabetic Neuropathy
Review: Several Classes of Drugs Treat Pain of Diabetic Neuropathy

MONDAY, March 27, 2017 (HealthDay News) -- Several classes of drugs reduce neuropathy-related pain better than placebo, according to a review published online March 24 in Neurology.

Julie M. Waldfogel, Pharm.D., from the Johns Hopkins Hospital in Baltimore, and colleagues conducted a systematic literature review to evaluate the effect of pharmacologic treatments of diabetic peripheral neuropathy (DPN) on pain and quality of life.

The researchers identified an additional 24 published studies and 25 unpublished studies, since the last completed systematic review of 57 eligible studies. Compared to placebo, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine (moderate strength of evidence [SOE]), the anticonvulsants pregabalin and oxcarbazepine (low SOE), the drug classes tricyclic antidepressants (low SOE) and atypical opioids (low SOE), and botulinum toxin (low SOE) were more effective for reducing neuropathy-related pain. Incomplete reporting prevented conclusions about quality of life. All evaluated studies were short-term (less than six months), and for all effective drugs, adverse effects caused >9 percent dropout rates.

"Future studies should evaluate longer-term outcomes, use methods, and measures recommended by pain organizations, and assess patients' quality of life," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Higher Fish Intake Appears to Reduce RA Symptoms

Higher Fish Intake Appears to Reduce RA Symptoms

Researchers suggest most varieties of fish may play a role in controlling symptoms

Longer Survival for Midostaurin  Chemotherapy in AML With FLT3

Longer Survival for Midostaurin + Chemotherapy in AML ...

Prolonged overall, event-free survival for patients with acute myeloid leukemia, FLT3 mutation

HIV Testing Inadequate in Young Men Who Have Sex With Men

HIV Testing Inadequate in Young Men Who Have ...

Only 28 percent of young MSM have HIV testing, though they account for 83 percent of new diagnoses

is free, fast, and customized just for you!

Already a member?

Sign In Now »